Results 161 to 170 of about 161,997 (305)

Renal sodium handling and neurohumoral systems in patients with cirrhosis in sitting posture [PDF]

, 1993
Gerbes, Alexander L., Jüngst, Dieter, Pilz, A., Wernze, Heinrich   +3 more
core   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa‐Rotter, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Shimoli V. Shah, Dick de Zeeuw, Katherine R. Tuttle   +14 more
wiley   +1 more source

Increased Frequency and Distinct Genotypic Patterns of Somatic Aldosterone-Driver Mutations in Aldosterone-Producing Micronodules from Primary Aldosteronism Patients. [PDF]

Endocr Pathol
Lim JS, Wu CY, Qin Z, Liu CJ, van Rooyen D, Sapiro DR, Giordano TJ, Turcu AF, Rainey WE, Udager AM.   +9 more
europepmc   +1 more source

Renal tubular acidosis in a mule mare

Equine Veterinary Education, EarlyView.
Summary Renal tubular acidosis (RTA) in horses is differentiated into type I (distal) and type II (proximal) forms. We report the diagnostic evaluation and treatment of type I RTA in a 13‐year‐old mule mare that was referred because of lethargy and inappetence of several weeks' duration as well as lack of manure, anorexia and mild colic for 3 days.
L. Kummer, K. Lohmann, C. Arnold
wiley   +1 more source

Baxdrostat: A First-in-Class Aldosterone Synthase Inhibitor for Resistant Hypertension. [PDF]

ACS Pharmacol Transl Sci
Capriello I, Dömling A.
europepmc   +1 more source

Unmasking Hormonal Mechanisms of Hypertension in Obesity. [PDF]

JACC Basic Transl Sci
Parisien-La Salle S, Tsai CH, Newman AJ, Chan JM, Milks J, Adler G, Ferrebus A, Hanna I, Mahrokhian S, Pitt B, Brown JM, Vaidya A.   +11 more
europepmc   +1 more source

Kinetic and structural characterisation of domain‐specific angiotensin I‐converting enzyme inhibition by captopril, rentiapril and zofenoprilat

The FEBS Journal, EarlyView.
Angiotensin I‐converting enzyme (ACE) contains two catalytic domains (nACE and cACE) and is a key therapeutic target for hypertension and cardiovascular disease. Current ACE inhibitors (ACEi) nonselectively inhibit both domains, causing adverse effects. Selective inhibition requires an understanding of domain‐specific binding.
Kyle S. Gregory, Vinasha Ramasamy, Edward D. Sturrock, K. Ravi Acharya   +3 more
wiley   +1 more source

Resistant hypertension and renal denervation: Who's kidding whom? [PDF]

, 2014
Sever, P
core   +1 more source

Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients With Cirrhosis and Hepatic Edema: A Nationwide Multicenter Cohort Study

Hepatology Research, EarlyView.
In a nationwide multicenter cohort, an early response to tolvaptan (≥ 1.5‐kg weight loss within 7 days) was independently associated with improved long‐term survival in patients with cirrhosis and hepatic edema. Early initiation before renal impairment or hyponatremia may optimize treatment response and prognosis. ABSTRACT Aim Hepatic edema indicates a
Kaori Koyano, Taeang Arai, Hidenori Toyoda, Keizo Kato, Joji Tani, Suguru Ogura, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Toshifumi Tada, Akito Nozaki, Atsushi Hiraoka, Kentaro Matsuura, Toru Ishikawa, Naoto Kawabe, Tsunamasa Watanabe, Koichi Takaguchi, Asahiro Morishita, Hironao Okubo, Motoh Iwasa, Hiroki Nishikawa, Yasuhito Tanaka, Masanori Atsukawa   +22 more
wiley   +1 more source

ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease [PDF]

, 2016
Adams LG, Adams LG, Barber PJ, Benigni A, Cowgill Ld, Cowgill LD, DiBartola SP, Finco DR, Goldstein RE, Grandy JL, Jensen J, Kirk CA, Lulich JP, Ross LA, Seefeldt SL, Sparkes AH, Steele JL, Stiles J, Tonkin L, Wagner E   +19 more
core   +1 more source